<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687152</url>
  </required_header>
  <id_info>
    <org_study_id>Micro Arginase</org_study_id>
    <nct_id>NCT02687152</nct_id>
  </id_info>
  <brief_title>Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes</brief_title>
  <official_title>Effect of Arginase Inhibition on Microvascular Endothelial Function in Patients With Type 2 Diabetes and Microvascular Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project is designed to test the hypothesis that arginase contributes to
      microvascular endothelial dysfunction in patients with type 2 diabetes and microvascular
      complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      The development of microvascular complications in diabetes is a complex process, in which
      endothelial dysfunction is of importance. Emerging evidence suggests that arginase is a key
      mediator of endothelial dysfunction in type 2 diabetes mellitus (T2DM) by reciprocally
      regulating nitric oxide bioavailability. The aim of this study was to test the hypothesis
      that arginase activity is increased and that arginase contributes to microvascular
      endothelial function in patients with T2DM and microvascular dysfunction.

      Method

      Microvascular endothelium-dependent and -independent vasodilatation are investigated in
      patients with T2DM (n =12) and healthy age-matched control subjects (n =12) with
      laser-Doppler flowmetry during iontophoretic application of acetylcholine and sodium
      nitroprusside, respectively, before and after intra-arterial administration of the arginase
      inhibitor N-hydroxy-nor-L-arginine (0.1 mg/min) for 120 min.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cutaneous microvascular endothelial function</measure>
    <time_frame>2 hours</time_frame>
    <description>Laser Doppler flow rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arginase inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>N-hydroxy-nor-L-arginine</intervention_name>
    <arm_group_label>Arginase inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of type 2 diabetes mellitus and microvascular dysfunction defined
             as microalbuminuria &gt; 3.0 mg/mmol or presence of retinopathy.

        Exclusion Criteria:

          -  Myocardial infarction or unstable angina within the last three months,

          -  Changed dose of any vasodilator drug during the preceding six weeks,

          -  Ongoing treatment with warfarin

          -  Concomitant disease that may have interfered with the possibility for the patients to
             comply with or complete the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pernow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>John Pernow</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

